Navigation Links
Telik Announces Publication of Review Focused on the Inhibition of the Enzyme GSTP1-1 as a Target for New Cancer Treatments
Date:7/12/2010

xn-location">the United States, with survival rates ranging from six months to six years.  MDS patients often require blood transfusions to manage their disease.

There remains a critical need for effective, well tolerated therapies for MDS.  Telintra has a novel mechanism of action that inhibits an enzyme called glutathione S-transferase P1-1 which may activate JNK kinase, a key regulator of cellular growth and differentiation of blood precursor cells.  Telintra has been shown to stimulate normal multilineage differentiation of blood stem cell precursors and induce cancer cell death, or apoptosis, in human leukemia cell lines.  Additional information on Telintra is available at www.telik.com.

About Telik

Telik, Inc. of Palo Alto, CA, is a clinical stage drug development company focused on discovering and developing small molecule drugs to treat cancer.  The company's most advanced drug candidates in clinical development are Telintra, a modified glutathione analog for the treatment of MDS and Severe Chronic Neutropenia (SCN), and Telcyta®, a cancer activated prodrug for the treatment of advanced non-small cell lung cancer and ovarian cancer.  Telik's product candidates were discovered using its proprietary drug discovery technology, TRAP®, which enables the rapid and efficient discovery of small molecule drug candidates.

Telik, the Telik logo, TELINTRA, TELCYTA and TRAP are trademarks or registered trademarks of Telik, Inc.


'/>"/>
SOURCE Telik, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Telik Announces Publication of a Case Report of a Sustained Hematologic Response in Myelodysplastic Syndrome Following an Abbreviated Exposure to Oral Telintra(R) (Ezatiostat HCl)
2. Telik Announces Fourth Quarter and 2009 Year End Financial Results and 2010 Financial Guidance
3. Telik Announces Initiation of Phase 1 Clinical Study of Ezatiostat Hydrochloride (TELINTRA(R), TLK199) Tablets in Combination With Lenalidomide (Revlimid(R)) in Patients With Myelodysplastic Syndrome (MDS)
4. Telik Announces Third Quarter 2009 Financial Results
5. Telik Announces Publication of Positive Phase 1-2a Results of a Multicenter Study of TELCYTA(R) in Combination With Carboplatin and Paclitaxel in Patients With Advanced Non-Small Cell Lung Cancer
6. Telik Announces Publication of Positive Phase 1 Results of a Multicenter Study of Ezatiostat Hydrochloride (TELINTRA(R), TLK199) Tablets In Patients With Myelodysplastic Syndrome
7. Telik Announces Presentation at ASCO Annual Meeting
8. Teliks Proteasome Inhibitor Program Meets a Preclinical Development Milestone
9. Telik Announces Initiation of Two Phase 2 Randomized TELINTRA Studies
10. Telik Announces Telintra Presentation at American Society of Hematology Annual Meeting
11. Telik Announces Preclinical Data Demonstrating Anti-Cancer Activity of Dual Inhibitors of Aurora Kinase and VEGFR2
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/10/2014)... , July 10, 2014  The U.S. Department of ... grant to University Hospitals (UH) Case Medical Center Seidman ... national model aimed at improving care for patients with ... the project will test a unique model developed at ... late-stage disease, significant comorbidities, or demonstrated need for high ...
(Date:7/10/2014)... DIEGO , July 10, 2014  RESMED INC. (NYSE: ... its fourth quarter and fiscal year ended June 30, 2014 ... Stock Exchange market close. A press release with ResMed,s results ... the company will host a webcast to discuss operating results ... to begin at 1:30 p.m. US Pacific Time and the ...
(Date:7/10/2014)... LAVAL, Quebec , July 10, 2014  Valeant ... TSX: VRX) today announced it has completed the sale ... Sculptra, and Dysport owned or held by Valeant for ... agreement with Nestle S.A, which recently completed its acquisition ... complete the divestiture of our products to a company ...
Breaking Medicine Technology:University Hospitals Case Medical Center Awarded $4.7 Million Grant from U.S. Department of Health and Human Services 2University Hospitals Case Medical Center Awarded $4.7 Million Grant from U.S. Department of Health and Human Services 3University Hospitals Case Medical Center Awarded $4.7 Million Grant from U.S. Department of Health and Human Services 4ResMed To Announce Fourth Quarter And Fiscal Year-End 2014 Results 2
... 2, 2011 ViroPharma Incorporated (Nasdaq: VPHM ) ... officer of ViroPharma, will present at the Jefferies 2011 Global ... 2011.  The conference is being held in New York City. ... through www.viropharma.com and available for a period of ...
... be presented in a poster at the 2011 Annual Meeting ... in Chicago, Illinois June 3-7 by researchers from The University ... that a laboratory test developed by Biocept, Inc. for the ... Disseminated Tumor Cells (DTCs) can provide potentially valuable information to ...
Cached Medicine Technology:MD Anderson and Biocept Scientists to Present Poster at ASCO on Disseminated Tumor Cells (DTCs) in Bone Marrow and Circulating Tumor Cells (CTCs) in Blood in Early Stage Breast Cancer Patients 2MD Anderson and Biocept Scientists to Present Poster at ASCO on Disseminated Tumor Cells (DTCs) in Bone Marrow and Circulating Tumor Cells (CTCs) in Blood in Early Stage Breast Cancer Patients 3
(Date:7/11/2014)... Volunteers from Scientology Churches and Missions are ... education lectures, forums and conferences, information stands, sports events, ... world. , Drug abuse is an international epidemic. According ... of alcohol and illicit drugs costs more than $425 ... and healthcare. , In the face of statistics ...
(Date:7/11/2014)... 11, 2014 The report, “Specialty ... Applications & Geography - 2018,” defines and segments ... with an analysis and forecast of the volumes ... fibers (Para aramids, meta aramids, UHMW Polyethylene, carbon ... PPS fiber, PBI fiber, PBO fiber, and liquid ...
(Date:7/11/2014)... 11, 2014 Utilizing the Keller Funnel, ... William Koenig, has topped a record number of complication-free ... performed over 400 successful procedures without the occurrence of ... well known across the country for his expertise with ... has long been the foundation for numerous studies and ...
(Date:7/11/2014)... 2014 (HealthDay News) -- Children who have emergency ... complications and potentially even death than those who ... However, the Johns Hopkins researchers noted that ... researchers analyzed data on nearly 440,000 simple emergency ... over a 22-year period. The surgeries are ...
(Date:7/11/2014)... The report “Probiotics Market by Products (Functional ... (Regular, Therapeutic, Preventive Health Care) & Ingredients (Lactobacilli, ... 2019 ” defines and segments the global probiotics ... market value of probiotic products and ingredients. The ... for the global market with an analysis of ...
Breaking Medicine News(10 mins):Health News:Scientologists Taking Action against Drug Abuse 2Health News:Scientologists Taking Action against Drug Abuse 3Health News:Specialty Synthetic Fibers & Glass Fiber Market Poised to Reach $20.1 Billion at a CAGR of 5.2% by 2018 – Report by MarketsandMarkets 2Health News:Specialty Synthetic Fibers & Glass Fiber Market Poised to Reach $20.1 Billion at a CAGR of 5.2% by 2018 – Report by MarketsandMarkets 3Health News:Specialty Synthetic Fibers & Glass Fiber Market Poised to Reach $20.1 Billion at a CAGR of 5.2% by 2018 – Report by MarketsandMarkets 4Health News:Rochester Surgeon Hits Milestone with Keller Funnel 2Health News:Emergency Surgeries on Weekends Riskier for Kids: Study 2Health News:Probiotic Ingredient Market worth $1,732.8 Million by 2019 - A Report by MarketsandMarkets 2Health News:Probiotic Ingredient Market worth $1,732.8 Million by 2019 - A Report by MarketsandMarkets 3Health News:Probiotic Ingredient Market worth $1,732.8 Million by 2019 - A Report by MarketsandMarkets 4Health News:Probiotic Ingredient Market worth $1,732.8 Million by 2019 - A Report by MarketsandMarkets 5
... experiences on anti-aging and ... personal beauty, ... public launch of the first consumer website dedicated,to consumer reviews and ... engage in an,open and honest conversation about important decisions that affect ...
... 11:00AM Adults with Attention Deficit Hyperactivity ... Extended-release Tablets showed significant improvements in ADHD symptom ... study results presented today at a major psychiatric ... adolescents with ADHD is clearly established but relatively ...
... Mid-Sized Companies Control Health Care Costs, DALLAS, ... Kenneth H. Cooper, M.D., M.P.H., Cooper Aerobics Enterprises,Inc., ... 37-year,history. Cooper Aerobics Enterprises purchased Health At Work, ... a new division, Cooper Benefits,LLC. Cooper Benefits ...
... have been found in related literature. One extremely rare ... of the World Journal of Gastroenterology because of its ... and sex factors, clinical and histopathological findings, diagnostic methods ... available literature. , The article reported one patient ...
... Ala. University of Alabama at Birmingham (UAB) researchers ... progression and switches on front-to-back body patterning in tadpoles. ... in understanding the complex DNA and cell interplay that ... and other diseases. , The UAB team focused on ...
... AMCS ),announces the following Webcast: (Logo: http://www.newscom.com/cgi-bin/prnh/20060202/AMICASLOGO ... 1, 2007 @ 8:30 AM ET, Where: http://www.videonewswire.com/event.asp?id=43463 ... on to the web at the address ... Inc, 617-779-7892. If you are unable to participate during the ...
Cached Medicine News:Health News:Consumers Open Up on RealSelf.com About 'Getting Work Done' 2Health News:Consumers Open Up on RealSelf.com About 'Getting Work Done' 3Health News:New study of Concerta showed significant improvement of ADHD symptom management in adults 2Health News:An Industry First: New Cooper Health Company Makes Group Employee Benefits Consulting and Wellness Program Design a Package Deal 2Health News:An Industry First: New Cooper Health Company Makes Group Employee Benefits Consulting and Wellness Program Design a Package Deal 3Health News:An Industry First: New Cooper Health Company Makes Group Employee Benefits Consulting and Wellness Program Design a Package Deal 4Health News:The largest colonic lipoma to date 2Health News:Cell pathway, disease linked to histone action 2
... polymerase chain reaction (PCR) to amplify and ... first to fully automate and integrate all ... sample preparation, DNA amplification and detection. Designed ... PCR test results from a raw sample ...
... For use as a non-reactive quality assurance reagent ... Toxoplasma gondii (TOXO IgG and TOXO IgM), IgG ... and rubella IgM), IgG and IgM antibodies to ... IgM antibodies to herpes simplex virus types 1 ...
... a fully automated system with,a disposable ... new refractive procedure known,as Epi-Lasik. The ... epithelium from the,Bowmans membrane leaving a ... the structural integrity,of the stroma and ...
... is a surgical/ mechanical device designed to ... the cornea above Bowman's layer. The Centurion ... used during LASEK to delaminate the epithelium. ... providing a 'minimal-touch' surgical approach, the SES ...
Medicine Products: